Skip to content

Geron GERN Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at other companies

Celcuity logo
CelcuityCELC
$145.19M+781%
Arcus Biosciences logo
Arcus BiosciencesRCUS
Tango Therapeutics logo
Tango TherapeuticsTNGX
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's total cash, cash equivalents, and restricted cash (inclusive).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's total cash, cash equivalents, and restricted cash (inclusive)?
Geron (GERN) reported total cash, cash equivalents, and restricted cash (inclusive) of $70.78M in Q1 2026.
How has Geron's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
Geron's total cash, cash equivalents, and restricted cash (inclusive) decreased by 17.3% year-over-year, from $85.61M to $70.78M.
What is the long-term trend for Geron's total cash, cash equivalents, and restricted cash (inclusive)?
Over 2 years (2023 to 2025), Geron's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 5.7% compound annual growth rate (CAGR), from $71.14M to $79.44M.